News | ASTRO | October 23, 2020

ASTRO Kicks Off Its Virtual Annual Meeting October 25

The virtual meeting's theme is Global Oncology: Radiation Therapy in a Changing World

Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.

October 23, 2020 — Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.

Originally planned as an on-site meeting in Miami, the ASTRO 2020 Annual Meeting was moved to a web-based platform due to safety concerns associated with the COVID-19 pandemic. Given the large volume of new science to be unveiled, the content will be available for 30 days after the meeting ends.

"Cancer doesn’t wait, even during a pandemic. With the health and safety of cancer patients in mind, we chose to invest in an interactive platform so that we can offer attendees a complete meeting experience,” said ASTRO President Thomas J. Eichler, M.D., FASTRO. “Attendees will be able to engage with each other on live video and chat platforms and access more than 2,500 abstracts. We will have live, on-demand and interactive sessions to showcase the latest research and best practices in cancer treatment. Recognizing that many meetings were cancelled or abbreviated this year, we enhanced our educational program and will have more than 200 hours of continuing medical education (CME) credits available for 30 days after the meeting ends.”

The meeting platform will include a digital rendering of the Miami Beach Convention Center that attendees can navigate to interact with other attendees and ASTRO leadership, visit networking lounges, participate in job interviews and attend live and on-demand sessions.

Additional highlights from the upcoming meeting include:

  • More than 2,500 abstract presentations, including a virtual poster hall with author narration and live Q&A, and more than 120 expert panels on topics such as COVID-19 and cancer treatment, implicit bias, immunotherapy, medical marijuana and patient safety
  • Cancer Breakthrough sessions where experts from ASCO, AACR, ESTRO and other leading medical societies will share the top advances in their fields from the past year
  • News briefings with live presentations of high-impact studies and Q&A with leading scientists (schedule to be announced in early October)
  • A keynote address from internationally renowned health economist Felicia M. Knaul, Ph.D., Director of the Institute for Advanced Study of the Americas at the University of Miami
  • A virtual Exhibit Hall where hundreds of exhibitors will offer product demonstrations and live discussions, as well as an Innovation Hub that will showcase new technologies like artificial intelligence and machine learning

For more information: www.astro.org

Related Content

The impact of deploying artificial intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.

Getty Images

News | Artificial Intelligence | June 15, 2021
June 15, 2021 — The impact of deploying ...
Rensselaer algorithm can identify risk of cardiovascular disease using lung cancer scan #CT
News | Computed Tomography (CT) | June 14, 2021
June 14, 2021 — Heart disease and cancer are the ...
A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.

Result of the Hoffman brain phantom study. Top row: same PET slice reconstructed with A) 2mm static OSEM, B) 1mm static OSEM, C) proposed SR method and D) corresponding CT slice (note that the CT image can be treated as a high-resolution reference). Middle row: zoom on region of interest for corresponding images. Bottom row: Line profiles for corresponding data. Image created by Y Chemli, et al., Gordon Center for Medical Imaging: Department of Radiology Massachusetts General Hospital, Harvard Medical School, Boston, MA.

News | PET Imaging | June 14, 2021
June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as...
Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

A) Axial CT images through the mouse lungs at 7 and 14 days after intratracheal administration of bleomycin or saline (as a control), demonstrating increased lung fibrosis in the bleomycin group (white arrows). (B) CT attenuation histograms in Hounsfield units (HU) after lung segmentation demonstrate increased attenuation in the lungs in the bleomycin group than the control group (p <0.05), consistent with increasing fibrosis (n=3). (C) Representative axial PET/CT fusion images at 20 and 60 min demonstrating increased FAPI uptake in the lungs of the bleomycin group (white arrows) with no significant uptake in the control group (yellow arrows). (D) Time-activity curve of lung uptake ROI analysis demonstrating higher FAPI uptake in the lungs of the bleomycin group than the control (p < 0.05), 14 days after bleomycin (n=3). (E) Ex vivo biodistribution data of lung tissue demonstrating higher radiotracer uptake in the lungs of the bleomycin group than the control (n=3). *p<0.05, **p<0.01. Image created by CA Ferreira et al., University of Wisconsin-Madison, Madison, WI.

News | PET-CT | June 14, 2021
June 14, 2021 — Positron emission tomography (PET) using
Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

News | SPECT Imaging | June 14, 2021
June 14, 2021 — An advanced artificial i...
Accuray Incorporated announced the company has received CE Mark certification for its ClearRT helical fan-beam kVCT imaging capability.
News | Radiation Therapy | June 11, 2021
June 11, 2021 — Accuray Incorporated announced the company has received CE Mark certification for its...
The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

News | X-Ray | June 10, 2021
June 10, 2021 — Engineers at Duke University have demonstrated a prot
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

Getty Images

News | PET Imaging | June 07, 2021
June 7, 2021 — The U.S.